Skip to main content

Table 2 Characteristics of ovarian clear cell carcinomas and potential molecular targets

From: Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives

Clinical features Mutated genes and overexpressed proteins Reference
Higher incidence among Asian women, particularly Japanese women ARID1A is mutated in 46 % of CCC patients (loss of function) [62, 85]
Clear cell carcinoma has a strong association with endometriosis PIK3CA is mutated in 33 % of CCC patients (activation mutation) [53]
Slow tumor growth, facilitating early detection Annexin A4 is expressed in almost all CCC patients [20, 22]
Strong resistance to platinum-based chemotherapy mTOR is overexpressed in 80 % of CCC patients [63]
Promising regimens with favorable and stable response for ovarian clear cell carcinoma have remained elusive HNF-1β is expressed in almost all CCC patients [52, 64, 7173]
Low frequency of BRCA1/2 mutations ZNF217 is overexpressed in 20 % of CCC patients [65]
Low frequency of p53 mutations (15 %) VEGF is strongly expressed in both early and advanced stages of CCC [66]
  EGFR is overexpressed in 60 % of CCC patients [59]
  MET is overexpressed in approximately 20 % of CCC patients [85]
  HER2 is overexpressed in 14–42.9 % of CCC patients [52, 53]
  PPMID expression is observed in 10 % of CCC patients [68]
  PPP2R1A is overexpressed in 7 % of CCC patients [52]
  KRAS is overexpressed in 5 % of CCC patients [52]
  1. ARID1A AT-rich interactive domain 1A (SWI-like) gene, BRCA 1/2 breast cancer susceptibility gene 1/2, EGFR epidermal growth factor receptor, HER2 human epidermal growth factor receptor 2, HNF-1β hepatocyte nuclear factor 1β, mTOR mammalian target of rapamycin, PIK3CA phosphoinositide 3-kinase catalytic-α, PPMID protein phosphatase magnesium-dependent, PP2R1A protein phosphatase 2, regulatory subunit A, VEGF vascular endothelial growth factor, ZNF217 zinc finger protein 217